Abstract:Abstract Background Proteins containing the Jumonji C (JmjC) domain participated in tumorigenesis and cancer progression. However, the mechanisms underlying this effect are still poorly understood. Our objective was to investigate the role of Jumonji and the AT‐rich interaction domain‐containing 2 (JARID2) — a JmjC family protein — in breast cancer, as well as its latent association with obesity. Methods Immunohistochemistry, The Cancer Genome Atlas, Gene Expression Omnibus, and other databases were used to analyze the expression of JARID2 in breast cancer cells. Growth curve, 5‐ethynyl‐2‐deoxyuridine (EdU), colony formation, and cell invasion experiments were used to detect whether JARID2 affected breast cancer cell proliferation and invasion. Spheroidization‐based experiments and xenotumor transplantation in NOD/SCID mice were used to examine the association between JARID2 and breast cancer stemness. RNA‐sequencing, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis were used to identify the cell processes in which JARID2 participates. Immunoaffinity purification and silver staining mass spectrometry were conducted to search for proteins that might interact with JARID2. The results were further verified using co‐immunoprecipitation and glutathione S‐transferase (GST) pull‐down experiments. Using chromatin immunoprecipitation (ChIP) sequencing, we sought the target genes that JARID2 and metastasis‐associated protein 1 (MTA1) jointly regulated; the results were validated by ChIP‐PCR, quantitative ChIP (qChIP) and ChIP‐reChIP assays. A coculture experiment was used to explore the interactions between breast cancer cells and adipocytes. Results In this study, we found that JARID2 was highly expressed in multiple types of cancer including breast cancer. JARID2 promoted glycolysis, lipid metabolism, proliferation, invasion, and stemness of breast cancer cells. Furthermore, JARID2 physically interacted with the nucleosome remodeling and deacetylase (NuRD) complex, transcriptionally repressing a series of tumor suppressor genes such as BRCA2 DNA repair associated ( BRCA2 ), RB transcriptional corepressor 1 ( RB1 ), and inositol polyphosphate‐4‐phosphatase type II B ( INPP4B ). Additionally, JARID2 expression was regulated by the obesity‐associated adipokine leptin via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway in the breast cancer microenvironment. Analysis of various online databases also indicated that JARID2/MTA1 was associated with a poor prognosis of breast cancer. Conclusion Our data indicated that JARID2 promoted breast tumorigenesis and development, confirming JARID2 as a target for cancer treatment.

JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte‐derived leptin

JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.

JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level

Jumonji and AT-Rich Interacting Domain 2 (JARID2) exhibits a tumor-suppressive role in Oral Squamous Cell Carcinoma by modulating tumor progression and metastasis

JMJD2A Contributes to Breast Cancer Progression Through Transcriptional Repression of the Tumor Suppressor ARHI

JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway

JAM2 Predicts a Good Prognosis and Inhibits Invasion and Migration by Suppressing EMT Pathway in Breast Cancer

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression

JARID2 Inhibits Leukemia Cell Proliferation by Regulating CCND1 Expression

High Expression of JAM2 Indicates Better Prognosis and Immunotherapy Response in Breast Cancer

Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14.

Jumonji Domain-Containing Protein 2B Silencing Induces DNA Damage Response Via STAT3 Pathway in Colorectal Cancer.

Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.

JARID2, a novel regulatory factor, promotes cell proliferation, migration, and invasion in oral squamous cell carcinoma

JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer

JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial–mesenchymal transition in lung adenocarcinoma

Aberrant expression of JAM2 inhibits invasion and migration in lung adenocarcinoma

Jumonji Domain Containing 2A Predicts Prognosis and Regulates Cell Growth in Lung Cancer Depending on Mir-150

The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)

Identification and Validation of JAM-A as a Novel Prognostic and Immune Factor in Human Tumors